Student or educator? Sign up with your school email and get 6 months of Pro free.
Cited by 214

The DOI matches its Crossref record; 4 of the 4 references it cites were found in a registry or an index.

Efficacy and safety of ustekinumab treatment in adults with moderate‐to‐severe atopic dermatitis

Open access
Khattri, Saakshi, Brunner, Patrick M., Garcet, Sandra, Finney, Robert, Cohen, Steven R., Oliva, Margeaux, Dutt, Riana, Fuentes‐Duculan, Judilyn, Zheng, Xiuzhong, Li, Xuan, Bonifacio, Kathleen M., Kunjravia, Norma, Coats, Israel, Cueto, Inna, Gilleaudeau, Patricia, Sullivan‐Whalen, Mary, Suárez‐Fariñas, Mayte, Krueger, James G., Guttman‐Yassky, Emma·2017·Experimental Dermatology

Abstract

Atopic dermatitis ( AD ) is the most common inflammatory skin disease, but treatment options for moderate‐to‐severe disease are limited. Ustekinumab is an IL ‐12/ IL ‐23p40 antagonist that suppresses T h1, T h17 and T h22 activation, commonly used for psoriasis patients. We sought to assess efficacy and safety of ustekinumab in patients with moderate‐to‐severe AD . In this phase II , double‐blind, placebo‐controlled study, 33 patients with moderate‐to‐severe AD were randomly assigned to either ustekinumab (n=16) or placebo (n=17), with subsequent crossover at 16 weeks, and last dose at 32 weeks. Background therapy with mild topical steroids was allowed to promote retention. Study endpoints included clinical ( SCORAD 50) and biopsy‐based measures of tissue structure and inflammation, using protein and gene expression studies. The ustekinumab group achieved higher SCORAD 50 responses at 12, 16 (the primary endpoint) and 20 weeks compared to placebo, but the difference between groups was not significant. The AD molecular profile/transcriptome showed early robust gene modulation, with sustained further improvements until 32 weeks in the initial ustekinumab group. Distinct and more robust modulation of T h1, T h17 and T h22 but also T h2‐related AD genes was seen after 4 weeks of ustekinumab treatment (i.e. MMP 12, IL ‐22, IL ‐13, IFN ‐γ, elafin/ PI 3, CXCL 1 and CCL 17; P <.05). Epidermal responses ( K 16, terminal differentiation) showed faster (4 weeks) and long‐term regulation (32 weeks) from baseline in the ustekinumab group. No severe adverse events were observed. Ustekinumab had clear clinical and molecular effects, but clinical outcomes might have been obscured by a profound “placebo” effect, most likely due to background topical glucocorticosteroids and possibly insufficient dosing for AD .

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1111/exd.13112

Cites

4 of 4 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Cited by

See all 214

Metadata

Authors
Khattri, S., Brunner, P. M., Garcet, S., Finney, R., Cohen, S. R., Oliva, M., Dutt, R., Fuentes‐Duculan, J., Zheng, X., Li, X., Bonifacio, K. M., Kunjravia, N., Coats, I., Cueto, I., Gilleaudeau, P., Sullivan‐Whalen, M., Suárez‐Fariñas, M., Krueger, J. G., & Guttman‐Yassky, E.
Venue
Experimental Dermatology
Publisher
Wiley
Published
2016-08-09
Volume
26
Issue
1
Pages
28-35
ISSN
  • 0906-6705 (ISSN-L)
  • 1600-0625
OpenAlex
W2432916178
Cited by
214
References
4
FWCI
31.77
Type
journal article
Language
en
Open access
green

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.